Our new paper "GLP-1-directed NMDA receptor antagonism for obesity treatment" is out today in @Nature
https://t.co/XmAbLIZ2FX
We describe the engineering and preclinical development of a new drug candidate that targets NMDA receptors in GLP-1 receptor neurons.
1/8 🧵👇
New review by Jonas Petersen, @TimoMueller_IDO, @clemmensenc et al.:
“The evolving landscape of obesity pharmacotherapy”
📖 @NatRevDrugDis | 🔗 https://t.co/pjHIKyttE3
👉 A timely overview of next-generation #obesity therapies beyond #GLP1.
The evolving landscape of obesity pharmacotherapy
https://t.co/g87Q1eGjgT
https://t.co/WBz2UaPWU2
This new Review covers the evolution of obesity therapy from GLP1s to multi-receptor agonists, oral formulations, weight-loss quality approaches and tissue-specific drug targeting
Our editor Revati Dewal (@revadewa3) will be attending this exciting symposium on the neuroendocrine control of energy metabolism in Copenhagen (DE) later this month. See below for more details, and reach out to her if you are attending and would like to chat! @DDEA_Denmark
If you are at #ECO2026 in Istanbul, come see data indicating that differences in feed efficiency might be a main explanation for why inbred 🐭 differ so much in HFD-induced weight gain ⚖️ 2/5
In Nature, @TimoMueller_IDO and colleagues describe a unimolecular conjugate that combines GLP-1R/GIPR co-agonism with pan-PPAR nuclear hormone receptor activation within a single therapeutic scaffold. @OdgaardJonas
https://t.co/dO1PGHTQ9h
@EricTopol Great to have this summarized - and I realize it’s indirectly there, but would be great with maybe 1-2 additional rows with a) preclinical/clinical evidence and b) robustness of said evidence
⏰ Deadline Dec 16 (11:59pm MST): Submit short talk & scholarship abstracts for the Gut–Brain Axis meeting. Join an all-star speaker lineup this March in Breckenridge, CO.
https://t.co/2lAT95NhVb
@tunepers#KSGutBrain26#gutbrainaxis#microbiome#gutsensing
DR is the oldest intervention to extend max lifespan, and still the strongest we have for mammals. Yet after a century of research, many key questions remain. In our latest @TheFangGroupUiO paper with 310+ refs in @NatureAging we try to answer this... 🧵🧵
https://t.co/ubybvmvyJ3
@philippefroguel@NatMetabolism@novonordisk Clarifications:
1) none of the authors are from @novonordisk
2) the abstract never says GLP-1R agonists should work in AD, it notes limited preclinical certainty and explains why clinical testing was warranted. EVOKE provided some of that clarity. Happy to share the full PDF.
New paper out in Aging Cell! We show how NMDA receptor modulation shapes metabolic control. Using memantine in C. elegans, we uncover effects on stress resilience, lifespan and energy metabolism. Led by @VaidaJuozaityte from @Metabolcenter
Open accees: https://t.co/LYbWRtqEYM
New review from the lab discussing the therapeutic potential of LEAP2 mimetics as an emerging strategy for treating obesity and related cardiometabolic disorders.
@Metabolcenter
https://t.co/muQlSuoq0V